The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Breakthrough Therapy Designation: Evaluation of trends and impact on CMC Strategies
Webinar On Demand
Breakthrough Therapy Designation (BTD) was introduced by the US FDA to help shorten the development and review time of novel drugs intended to treat serious or life-threatening diseases. To qualify, preliminary evidence must show the drug may demonstrate substantial clinical improvement over available treatments. Assignment of BTD may lead to accelerated clinical programs, which could be two or more years faster than a “conventional” development program. When the clinical program is accelerated, applicants face challenges to complete quality and manufacturing development and data requirements within the condensed drug development timelines.
Join us as drug product expert Anil Kane and regulatory affairs expert Betty Thompson discuss the problem and dive deep into topics including:
- Trends in breakthrough therapy designation in recent years
- CMC implications of an accelerated timeline
- Strategies to accelerate your clinical program